Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conference

(SeaPRwire) –   Halle (Saale) / Munich, Germany, April 9, 2026 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage biotechnology firm specializing in the development of small molecule therapeutics for inflammatory and fibrotic conditions, with a specific emphasis on kidney-related diseases, announced today that members of its management team will attend the upcoming investor event listed below:

Van Lanschot Kempen Life Sciences Conference
Date: April 16, 2026
Location: Amsterdam, The Netherlands
Attendee: Dr. Julia Neugebauer, COO

###

About Vivoryon Therapeutics N.V.

Vivoryon is a clinical-stage biotech company dedicated to creating novel small molecule medicines to treat inflammatory and fibrotic kidney disorders. Driven by a commitment to scientific excellence and innovation, the company aims to enhance patient care by altering the progression of serious diseases through the modulation of pathologically significant protein activity and stability. The company’s lead candidate, varoglutamstat—a proprietary, first-in-class oral QPCT/L inhibitor—is currently undergoing evaluation for the treatment of diabetic kidney disease. www.vivoryon.com

Vivoryon Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, those concerning the company’s business strategy, management objectives for future operations, market estimates and projections for its products, and anticipated availability timelines. Terms such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should,” and “will,” along with similar terminology, are used to denote these forward-looking statements. Such statements do not guarantee future performance and are based on current management expectations and assumptions regarding future trends, economic conditions, and other factors. These statements are subject to various known and unknown risks and uncertainties that could cause actual results, financial outcomes, or events to differ materially from those projected. Consequently, readers should not place undue reliance on these statements. This release does not detail specific risk factors; however, such factors are addressed in the company’s published annual financial reports. This document, including all forward-looking statements, is current only as of the date of publication. The company assumes no obligation to update any information or forward-looking statements, except as required by law.

For more information, please contact:
Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com

LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com

Attachment

• 2026-04-09_VVY_kempen